Sugammadex dosing: 2, 4 and 16 mg/kg

The dose is the easy part. The re-dosing interval, the body weight to use, and the discharge counseling are what get missed.

Reviewed and updated August 2026 · Written by Anastasia Jackson, DNAP, CRNA

Every clinical claim on this page is cited to its source below. How we source clinical content — including the corrections we have made and why.

Three doses, chosen by depth of block rather than by weight band. The dose itself is the easy part — the parts that get missed are the re-dosing interval, the body weight to use, and the counseling that has to happen before the patient goes home.

Six things that are not the dose

1. Actual body weight, not ideal

A randomized trial in adults with BMI ≥ 40 compared 2 mg/kg and 4 mg/kg dosed by actual versus ideal body weight, and actual body weight gave faster reversal.¹ The manufacturer specifies actual body weight for all patients including those with obesity; ideal body weight dosing risks underdosing, and underdosing is the specific route to recurrence.^2,7

2. Lower-than-recommended doses cause recurrence

There is an active research question about whether much smaller titrated doses are adequate — one trial titrated in 50 mg increments to a train-of-four ratio ≥ 0.9⁵ — but that is a study protocol, not current practice.

3. Re-dosing rocuronium afterward

The intervals depend on renal function and on which rocuronium dose you intend to give. The first two rows are the routine case.

4. Hormonal contraception — the counseling that gets missed

Sugammadex binds progestogen. A bolus dose is considered equivalent to missing a dose of an oral contraceptive containing estrogen or progestogen.^3,7

• Oral contraceptive taken the same day: the patient must use an additional non-hormonal method — condoms and spermicide — for the next 7 days.^3,7
• Non-oral hormonal contraception (implant, patch, ring, injection, hormonal IUD): the same 7-day additional non-hormonal method applies.^7,8
• Reported research suggests a 4 mg/kg dose can decrease progesterone exposure by approximately 34%.⁸

This is a discharge conversation and a discharge document, not a chart note. A patient who is asleep when the drug is given and drowsy when they leave has no way to know it happened.

5. Bradycardia, and how it is given

Marked bradycardia has been reported within minutes of administration, some cases resulting in cardiac arrest.^3,4 The manufacturer specifies rapid IV push over 10 seconds; some authors suggest a slower push to reduce the incidence of bradycardia or asystole.⁹ Have an antimuscarinic available.

Against that, the pooled comparison with neostigmine favors sugammadex substantially: composite adverse events RR 0.60 (0.49–0.74) across 28 studies, with bradycardia RR 0.16 (0.07–0.34) and residual paralysis RR 0.40 (0.28–0.57).⁸

6. Renal impairment

Sugammadex is eliminated unchanged by the kidney and the sugammadex–rocuronium complex depends on renal clearance. It is not recommended below a creatinine clearance of 30 mL/min, including in patients requiring dialysis.^4,7,10

Smaller points worth knowing

• Coagulation. Doses up to 16 mg/kg were associated with increases in aPTT and INR of up to 25% for up to one hour in healthy volunteers. Bleeding risk at 16 mg/kg has not been evaluated in patients on therapeutic anticoagulation or with known coagulopathy — monitor coagulation in those patients.⁴
• Anaphylaxis. In a placebo-controlled study of 299 healthy volunteers, the frequency of anaphylaxis was 0.3% — one case in the 16 mg/kg group.¹¹
• Toremifene binds sugammadex with relatively high affinity and can displace rocuronium or vecuronium from the complex, causing recurrence.^4,6
• Progesterone assay interference has been observed for up to 30 minutes after a 16 mg/kg dose.^7,9
• Light anesthesia. Movement, coughing, grimacing or suckling on the tube may appear if blockade is reversed while the patient is still anesthetized.²
• Pediatric: 2 mg/kg is the recommended dose for moderate block in children aged 2 to 17.¹²

Frequently asked questions

What is the dose of sugammadex?

2 mg/kg for moderate block (second twitch present on train-of-four), 4 mg/kg for deep block (no train-of-four twitches but 1–2 post-tetanic counts), and 16 mg/kg for immediate reversal roughly 3 minutes after rocuronium 1.2 mg/kg. All by actual body weight.⁷

Do you use actual or ideal body weight for sugammadex in an obese patient?

Actual body weight — the label states it directly.⁷ A randomized trial in adults with BMI ≥ 40 found actual body weight dosing gave faster reversal than ideal body weight at both 2 and 4 mg/kg,¹ and ideal body weight dosing risks underdosing, which is the specific route to recurrence of blockade.^2,3

How long after sugammadex can you give rocuronium again?

With normal renal function, 5 minutes if you are giving rocuronium 1.2 mg/kg, or 4 hours for rocuronium 0.6 mg/kg or vecuronium 0.1 mg/kg.⁷ After a 16 mg/kg dose, a 24-hour wait is suggested, and 24 hours also applies after up to 4 mg/kg in mild to moderate renal impairment — where, if a shorter interval is needed, rocuronium 1.2 mg/kg should be used.^2,7 If blockade is required before the wait elapses, use a non-steroidal agent, but expect slower onset because postjunctional receptors may still be occupied.⁶

Does sugammadex affect birth control?

Yes. It binds progestogen, and a bolus dose is considered equivalent to missing a dose of an oral contraceptive containing estrogen or progestogen.^3,7 Patients using any hormonal contraception — oral or non-oral — must use an additional non-hormonal method for 7 days afterward.^7,8 A 4 mg/kg dose has been reported to decrease progesterone exposure by around 34%.⁸ This needs to be a discharge conversation, since the patient was asleep when it was given.

Can sugammadex be used in renal failure?

It is not recommended below a creatinine clearance of 30 mL/min, including in patients requiring dialysis, because it is eliminated unchanged by the kidney and the sugammadex–rocuronium complex depends on renal clearance.^4,7,10

Why not just give a smaller dose of sugammadex?

Because the label warns specifically that lower than recommended doses increase the risk of recurrence of blockade after initial reversal.^3,4 Titrated low-dose strategies are under study⁵ but are not current practice, and a small number of patients show a delayed or minimal response even at full dose — so ventilation should be monitored until recovery is confirmed.³

Does sugammadex cause bradycardia?

It can. Marked bradycardia has been reported within minutes of administration, some cases resulting in cardiac arrest.^3,4 Overall, though, pooled comparison with neostigmine favors sugammadex — bradycardia RR 0.16 (0.07–0.34) across the pooled trials.⁸

References

1. Horrow JC, Li W, Blobner M, et al. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial. BMC Anesthesiol. 2021;21:62. doi:10.1186/s12871-021-01278-w
2. Sugammadex monograph for professionals. Drugs.com. Re-administration wait times, renal impairment guidance, and light-anesthesia signs.
3. Sugammadex sodium prescribing information, safety warnings section. Bradycardia and cardiac arrest, delayed or minimal response, recurrence with lower than recommended dosing, and the oral contraceptive equivalence statement.
4. Bridion (sugammadex sodium) dosing, indications, interactions and adverse effects. Medscape Reference. Coagulation parameter changes at 16 mg/kg, toremifene displacement, renal threshold.
5. Sugammadex titration in cardiac surgery patients. ClinicalTrials.gov NCT05246397. Protocol describing titration in 50 mg increments to a train-of-four ratio of 0.9 or greater.
6. Sugammadex injection: prescribing information. DailyMed / Drugs.com professional monograph. Use of a non-steroidal agent if blockade is needed sooner, with the caveat about delayed depolarizing onset.
7. BRIDION (sugammadex) injection. US FDA prescribing information, via DailyMed. Source for the 2, 4 and 16 mg/kg indications and their depth-of-block criteria; “BRIDION dosing is based on actual body weight”; the re-administration waiting times (5 minutes for rocuronium 1.2 mg/kg, 4 hours for rocuronium 0.6 mg/kg or vecuronium 0.1 mg/kg, 24 hours in mild–moderate renal impairment and after 16 mg/kg); the delayed onset and shortened duration when rocuronium 1.2 mg/kg is given within 30 minutes of reversal; the 7-day non-hormonal contraception advice; progesterone assay interference; and the severe renal impairment exclusion.
8. Sugammadex advice for women of childbearing age. Includes the reported 34% reduction in progesterone exposure at 4 mg/kg, the 7-day non-hormonal advice for non-oral contraceptive users, and the pooled sugammadex-versus-neostigmine adverse event data (28 studies, n = 2,298).
9. Sugammadex: dosage, mechanism and onset of action. Includes the administration-rate discussion (10-second push per manufacturer; slower push suggested by some authors) and progesterone assay interference.
10. Guidelines for the use of sugammadex and neostigmine/glycopyrrolate. Beth Israel Deaconess Medical Center Department of Anesthesia clinical pathway. Renal threshold and the case for reversal irrespective of twitch count in patients at risk of respiratory compromise.
11. Safety of sugammadex for the reversal of neuromuscular blockade in ASA class 3 or 4 participants (MK-8616-145). ClinicalTrials.gov NCT03346057. Anaphylaxis frequency of 0.3% in 299 healthy volunteers.
12. Ji SH, Huh KY, Oh J, et al. Conventional reversal of rocuronium-induced neuromuscular blockade by sugammadex in Korean children: pharmacokinetics, efficacy, and safety analyses. Front Pharmacol. 2023;14:1127932. doi:10.3389/fphar.2023.1127932